37 results about "Infantile haemangioma" patented technology

The present invention relates to methods and compositions designed for the treatment, management, prevention and / or amelioration of non-neoplastic hyperproliferative epithelial and / or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and / or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g., fibrosis of the liver, kidney, lungs, heart, retina and other viscera), asthma, ischemia, atherosclerosis, diabetic retinopathy, retinopathy of prematurity, vascular restenosis, macular degeneration, rheumatoid arthritis, osteoarthritis, infantile hemangioma, verruca vulgaris, Kaposi's sarcoma, neurofibromatosis, recessive dystrophic epidermolysis bullosa, ankylosing spondylitis, systemic lupus, Reiter's syndrome, Sjogren's syndrome, endometriosis, preeclampsia, atherosclerosis, coronary artery disease, psoriatic arthropathy and psoriasis. The methods of the invention comprise the administration of an effective amount of one or more agents that are modulators of EphA2 and / or its endogenous ligand, EphrinA1. The invention also provides pharmaceutical compositions comprising one or more EphA2 / EphrinA1 Modulators of the invention either alone or in combination with one or more other agents useful for therapy for such non-neoplastic hyperproliferative epithelial and / or endothelial disorders. Diagnostic methods and methods for screening for EphA2 / EphrinA1 Modulators are also provided.

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.

Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

Transdermal delivery of beta blockers to treat Infantile Hemangiomas.

The invention relates to the technical field of medicine and provides propranolole hydrochloride gel and a preparation method thereof. The propranolole hydrochloride gel is mainly prepared from the ingredients of bulk drug propranolole hydrochloride, penetration enhancer, humectant, preservative, gel substrate and water. A propranolole hydrochloride gel preparation prepared by the invention has the characteristics of being even, fine, appropriate in viscosity, easy to smear and free of irritation to skin; when being applied to treating subcutaneous-layer infantile hemangioma, the propranolole hydrochloride gel preparation is convenient to dose and avoids a first-pass effect of the liver; furthermore, the gel preparation can form a drug storage library on the skin, so that a slow-release function is achieved; meanwhile, the gel preparation is better in child patient adaptability and has good application prospect.

The invention discloses an itraconazole drop and a preparation method thereof, comprising the following components: 1-3 parts by weight of itraconazole, 80-120 parts by weight of vitamin E acetate, 5-15 parts by weight of vitamin A1, 10-30 parts by weight of PEG400. In the itraconazole drops disclosed in the invention, the itraconazole is in a dissolved state and has good stability, and can be directly absorbed without a dissolution step in the gastrointestinal tract, which is beneficial to improve bioavailability. In addition, the preparation process is simple, the auxiliary materials are high in safety, can be administered with milk or added to milk for administration, and is especially suitable for the treatment of infantile hemangioma.

The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.

The invention relates to a compound propranolol hydrochloride oral liquid for treating hemangioma in children, which comprises the following raw materials by weight: 100-300g of Gallus gallis, 200-400g of Hawthorn, 100-300g of Snakeberry, and 200-300g of Purple Pearl Leaf , Salvia miltiorrhiza 200-400g, lotus leaf 100-300g and propranolol hydrochloride 30-50g; Compared with the prior art, the present invention has significantly improved quality and effect, high cure rate, low adverse reaction rate, and good mouthfeel , easy to administer to children, small dosage, good bioavailability, and huge social and economic benefits.